PCSK9 inhibition: the way forward in the treatment of dyslipidemia

Barely a decade after the discovery of the gene encoding proprotein convertase subtilisin/kexin type 9 (PCSK9) and its recognition as a key player in cholesterol metabolism, PCSK9 inhibition is now considered an exciting approach in the reduction of residual risk of cardiovascular disease. The progr...

Descripción completa

Detalles Bibliográficos
Autores principales: Stoekenbroek, Robert M., Kastelein, John JP, Huijgen, Roeland
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4601145/
https://www.ncbi.nlm.nih.gov/pubmed/26456772
http://dx.doi.org/10.1186/s12916-015-0503-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4601145/
https://www.ncbi.nlm.nih.gov/pubmed/26456772
http://dx.doi.org/10.1186/s12916-015-0503-4

Ejemplares similares